Literature DB >> 32797361

Hierarchical cluster analysis of cytokine profiles reveals a cutaneous vasculitis-associated subgroup in dermatomyositis.

Jingjing Bai1, Chanyuan Wu1, Danli Zhong1, Dong Xu1, Qian Wang2, Xiaofeng Zeng3.   

Abstract

OBJECTIVES: Dermatomyositis (DM) is a chronic inflammatory autoimmune disease with notable heterogeneity. The intent of this study was to explore the difference in cytokine profiles of different subsets in DM based on the disease activity and myositis-specific antibodies, and to identify the clinical phenotypes associated with different cytokine profiles.
METHODS: Serum levels of 34 cytokines were prospectively measured in 47 consecutive DM patients and healthy controls. Concentrations of the cytokines were compared between the active and stable groups. Univariate and multivariate logistic regression models were used to identify the cytokines associated with DM disease activity. The cytokine profiles of anti-MDA5 and anti-TIF1γ subsets were compared, and the correlation analysis was performed between the elevated cytokines and clinical parameters in the two subsets. Hierarchical cluster analysis was used to establish clinical-cytokine subgroups in DM.
RESULTS: Serum levels of MIP-1α, IP-10, IL-8, IL-1RA, MCP-1, GRO-α, and IL-22 were significantly higher in DM patients compared with healthy controls. IP-10, IL-6, IL-1RA, IFN-α, and MCP-1 were significantly elevated in the DM-active subset than the DM-stable subset. The combination of three cytokines (IP-10, IL-1RA, and MCP-1) had a better performance in differentiating between the active subset and the stable subset than the conventional inflammatory markers. SDF-1α, IP-10, IL-7, IL-17A, RANTES, IFN-γ, TNF-α, MIP-1β, IFN-α, MCP-1, GRO-α, and IL-1α were significantly higher in the anti-MDA5 subset than in the TIF1γ subset. Cluster analysis revealed a hypercytokinemic-vasculitis subgroup in patients with DM.
CONCLUSIONS: Multiple cytokine signatures were depicted in different subsets of DM. A vasculitis-associated subgroup was firstly identified in DM with regards of cytokinome and deserves further mechanistic study. Key Points • The multivariate regression model of three cytokines (IP-10, IL-1RA, and MCP-1) could be a promising tool for distinguishing between the active and stable subset in DM. • Cytokine profiles of anti-MDA5-DM and anti-TIF1γ-DM were compared to identify the immunopathological differences between the two subsets. • Cluster analysis revealed a hypercytokinemic-vasculitis subgroup in patients with DM.

Entities:  

Keywords:  Cluster analysis; Cutaneous vasculitis; Cytokine; Dermatomyositis

Mesh:

Substances:

Year:  2020        PMID: 32797361     DOI: 10.1007/s10067-020-05339-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?

Authors:  Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2002-04       Impact factor: 11.527

3.  High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.

Authors:  David A Lynch; J David Godwin; Sharon Safrin; Karen M Starko; Phil Hormel; Kevin K Brown; Ganesh Raghu; Talmadge E King; Williamson Z Bradford; David A Schwartz; W Richard Webb
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

4.  Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.

Authors:  Sei-Ichiro Motegi; Akiko Sekiguchi; Sayaka Toki; Chikako Kishi; Yukie Endo; Masahito Yasuda; Hidekazu Ikeuchi; Toru Sakairi; Kenichiro Hara; Koichi Yamaguchi; Toshitaka Maeno; Keiju Hiromura; Osamu Ishikawa
Journal:  Eur J Dermatol       Date:  2019-10-01       Impact factor: 3.328

5.  Clinically amyopathic dermatomyositis: what can we now tell our patients?

Authors:  Richard D Sontheimer
Journal:  Arch Dermatol       Date:  2010-01

6.  The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.

Authors:  Audrey Aussy; Manuel Fréret; Laure Gallay; Didier Bessis; Thierry Vincent; Denis Jullien; Laurent Drouot; Fabienne Jouen; Pascal Joly; Isabelle Marie; Alain Meyer; Jean Sibilia; Brigitte Bader-Meunier; Eric Hachulla; Mohammed Hamidou; Sophie Huë; Jean-Luc Charuel; Nicole Fabien; Pierre-Julien Viailly; Yves Allenbach; Olivier Benveniste; Nadège Cordel; Olivier Boyer
Journal:  Arthritis Rheumatol       Date:  2019-07-08       Impact factor: 10.995

Review 7.  Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

8.  Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.

Authors:  Katsuaki Asakawa; Kazutaka Yoshizawa; Ami Aoki; Yosuke Kimura; Takahiro Tanaka; Kazumasa Ohashi; Masachika Hayashi; Toshiaki Kikuchi; Shinji Sato; Toshinori Takada
Journal:  Clin Rheumatol       Date:  2020-02-13       Impact factor: 2.980

9.  Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.

Authors:  David F Fiorentino; Karen Kuo; Lorinda Chung; Lisa Zaba; Shufeng Li; Livia Casciola-Rosen
Journal:  J Am Acad Dermatol       Date:  2015-01-14       Impact factor: 11.527

10.  Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52.

Authors:  Yoshioki Yamasaki; Minoru Satoh; Machiko Mizushima; Takahiro Okazaki; Hiroko Nagafuchi; Seido Ooka; Tomohiko Shibata; Hiromasa Nakano; Hitoshi Ogawa; Kohei Azuma; Akihiko Maeda; Kumiko Tonooka; Hiroshi Ito; Yukiko Takakuwa; Makoto Inoue; Hirofumi Mitomi; Tomofumi Kiyokawa; Kosei Tsuchida; Hiromi Matsushita; Hidenori Mikage; Yoshihiko Murakami; Jason Y F Chan; Shoichi Ozaki; Hidehiro Yamada
Journal:  Mod Rheumatol       Date:  2015-10-19       Impact factor: 3.023

View more
  5 in total

Review 1.  Update on Biomarkers of Vasculopathy in Juvenile and Adult Myositis.

Authors:  Kirsty McLellan; Charalampia Papadopoulou
Journal:  Curr Rheumatol Rep       Date:  2022-06-10       Impact factor: 4.686

Review 2.  Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry.

Authors:  Pankti Mehta; Pedro M Machado; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-03-27       Impact factor: 2.631

Review 3.  Pathogenesis of Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis: A Concise Review With an Emphasis on Type I Interferon System.

Authors:  Huifang Hu; Hang Yang; Yi Liu; Bing Yan
Journal:  Front Med (Lausanne)       Date:  2022-01-24

4.  The Expression of Cytokine Profiles and Related Receptors in Idiopathic Inflammatory Myopathies.

Authors:  Junyu Zhou; Lijuan Zhao; Yizhi Xiao; Shasha Xie; Ying Long; Yu Wei; Qiming Meng; Xiaojing Li; Hui Luo; Honglin Zhu
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

5.  Hsp90 as a Myokine: Its Association with Systemic Inflammation after Exercise Interventions in Patients with Myositis and Healthy Subjects.

Authors:  Xiao Švec; Hana Štorkánová; Maja Špiritović; Kryštof Slabý; Sabína Oreská; Aneta Pekáčová; Barbora Heřmánková; Kristýna Bubová; Petr Česák; Haya Khouri; Gulalai Amjad; Heřman Mann; Martin Komarc; Karel Pavelka; Ladislav Šenolt; Josef Zámečník; Jiří Vencovský; Michal Tomčík
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.